Evidence map›Paper›PMID 41188257›Full record

ArticleNPJ systems biology and applications2025

Modeling tumor dynamics and predicting response to therapies in a murine pancreatic cancer model.

Krithik Vishwanath, Hoon Choi, Mamta Gupta, Rong Zhou, Anna G Sorace, Thomas E Yankeelov, Ernesto A B F Lima

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ systems biology and applications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. The Next Frontier in Quantitative Co-Clinical Imaging to Advance Functional Precision Oncology.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Krithik VishwanathOden Institute for Computational Engineering and Sciences, The University of Texas at Austin, Austin TX, USA. krithik.vish@utexas.edu.
Hoon ChoiDepartment of Radiology, The University of Pennsylvania, Philadelphia PA, USA.
Mamta GuptaDepartment of Radiology, The University of Pennsylvania, Philadelphia PA, USA.
Rong ZhouDepartment of Radiology, The University of Pennsylvania, Philadelphia PA, USA.
Anna G SoraceDepartment of Radiology, The University of Alabama, Birmingham, Birmingham AL, USA.
Thomas E YankeelovOden Institute for Computational Engineering and Sciences, The University of Texas at Austin, Austin TX, USA.
Ernesto A B F LimaOden Institute for Computational Engineering and Sciences, The University of Texas at Austin, Austin TX, USA. ernesto.lima@utexas.edu.

Funding

INTEGRATING OMICS AND QUANTITATIVE IMAGING DATA IN CO-CLINICAL TRIALS TO PREDICT TREATMENT RESPONSE IN TRIPLE NEGATIVE BREAST CANCERU24CA226110 · NCI · BAYLOR COLLEGE OF MEDICINE · PI LEWIS, MICHAEL T., RUBIN, DANIEL L · 2019 to 2023
$3.2M
Penn Quantitative MRI Resource for Pancreatic CancerU24CA231858 · NCI · UNIVERSITY OF PENNSYLVANIA · PI ODWYER, PETER J, ROSEN, MARK ALAN · 2018 to 2022
$3.0M
Personalizing immunotherapy in HER2+ breast cancer through quantitative imagingR01CA240589 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SORACE, ANNA C · 2020 to 2023
$1.6M
Mathematical modeling and molecular imaging to maximize response while minimizing toxicities from systemic therapies in preclinical models of breast cancerR01CA276540 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SORACE, ANNA C, YANKEELOV, THOMAS E · 2023 to 2025
$1.4M
American Cancer Society RSG-18-006-01-CCCancer Prevention and Research Institute of Texas,United States CPRIT RR16000NCI NIH HHS R01 CA240589NCI NIH HHS R01 CA276540NCI NIH HHS U24 CA226110NCI NIH HHS U24 CA231858NIH HHS R01CA240589NIH HHS R01CA276540NIH HHS U24CA231858
6 · The paper itself

Abstract

We seek to establish a parsimonious mathematical framework for understanding the interaction and dynamics of the response of pancreatic cancer to the NGC triple chemotherapy regimen (mNab-paclitaxel, gemcitabine, and cisplatin), stromal-targeting drugs (calcipotriol and losartan), and an immune checkpoint inhibitor (anti-PD-L1). We developed a set of ordinary differential equations describing changes in tumor size under the influence of cocktails of treatments. Parameter estimation relies on three tumor volume measurements obtained over a 14-day period in a genetically engineered pancreatic cancer model (

Indexed as

Models, BiologicalPancreatic NeoplasmsAnimalsAntineoplastic Combined Chemotherapy ProtocolsCalcitriolCisplatinDeoxycytidineDisease Models, AnimalGemcitabineHumansLosartanMicePaclitaxelTumor BurdencalcipotrieneCalcitriolCisplatinDeoxycytidineGemcitabineLosartanPaclitaxel

Identifiers

PMID41188257
PMCPMC12586507

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.